Evidence map›Paper›PMID 39822019›Full record

ArticleCancer science2025

Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications.

Yuko Chikaishi, Hiroshi Matsuoka, Eiji Sugihara, Mayu Takeda, Makoto Sumitomo, Seiji Yamada, Gaku Inaguma, Yusuke Omura, Yeongcheol Cheong, Yosuke Kobayashi and 8 more

Abstract read
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuko ChikaishiDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Hiroshi MatsuokaDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Eiji SugiharaResearch Promotion Headquarters, Open Facility Center, Fujita Health University, Toyoake, Japan.
Mayu TakedaFaculty of Health and Medical Sciences, Aichi Syukutoku University, Nagakute, Aichi, Japan.
Makoto SumitomoOncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.
Seiji YamadaOncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.
Gaku InagumaDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Yusuke OmuraDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Yeongcheol CheongDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Yosuke KobayashiDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Masaya NakauchiDepartment of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Junichiro HiroDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Koji MasumoriDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Koki OtsukaDepartment of Advanced Robotic and Endoscopic Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Hiroshi NishiharaCenter for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5460-8703
Koichi SudaDepartment of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Hideyuki SayaOncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.
Tetsuya TakimotoOncology Innovation Center, Fujita Health University, Toyoake, Aichi, Japan.ORCID https://orcid.org/0009-0009-3008-8078

Funding

Japan Society for the Promotion of Science KAKENHI 23H00410
6 · The paper itself

Abstract

Colorectal cancer (CRC) is well characterized in terms of genetic mutations and the mechanisms by which they contribute to carcinogenesis. Mutations in APC, TP53, and KRAS are common in CRC, indicating key roles for these genes in tumor development and progression. However, for certain tumors with low frequencies of these mutations that are defined by tumor location and molecular phenotypes, a carcinogenic mechanism dependent on BRAF mutations has been proposed. We here analyzed targeted sequence data linked to clinical information for CRC, focusing on tumors with a high tumor mutation burden (TMB) in order to identify the characteristics of associated mutations, their relations to clinical features, and the mechanisms of carcinogenesis in tumors lacking the major driver oncogenes. Analysis of overall mutation frequencies confirmed that APC, TP53, and KRAS mutations were the most prevalent in our cohort. Compared with other tumors, TMB-high tumors were more frequent on the right side of the colon, had lower KRAS and higher BRAF mutation frequencies as well as a higher microsatellite instability (MSI) score, and showed a greater contribution of a mutational signature associated with MSI. Ranking of variant allele frequencies to identify genes that play a role early in carcinogenesis suggested that mutations in genes related to the DNA damage response (such as ATM and POLE) and to MSI (such as MSH2 and MSH6) may precede BRAF mutations associated with activation of the serrated pathway in TMB-high tumors. Our results thus indicate that TMB-high tumors suggest that mutations of genes related to mismatch repair and the DNA damage response may contribute to activation of the serrated pathway in CRC.

Indexed as

Colorectal NeoplasmsMutationAdenomatous Polyposis Coli ProteinAgedBiomarkers, TumorDNA Mutational AnalysisFemaleGene FrequencyHumansMaleMicrosatellite InstabilityMiddle AgedProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Adenomatous Polyposis Coli ProteinBiomarkers, TumorBRAF protein, humanKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53colorectal cancerCpG island methylator phenotype (CIMP)molecular phenotypeprecision medicinetumor mutation burden (TMB)

Identifiers

PMID39822019
PMCPMC11967252

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.